Morgan R Firestein,Lauren C Shuffrey,Yunzhe Hu,Margaret Kyle,Maha Hussain,Catherine Bianco,Violet Hott,Sabrina P Hyman,Mia Kyler,Cynthia Rodriguez,Melanie Tejeda Romero,Helen Tzul Lopez,Carmela Alcántara,Dima Amso,Judy Austin,Jennifer M Bain,Jennifer Barbosa,Ashley N Battarbee,Ann Bruno,Sharon Ettinger,Pam Factor-Litvak,Suzanne Gilboa,Sylvie Goldman,Cynthia Gyamfi-Bannerman,Panagiotis Maniatis,Rachel Marsh,Tyler Morrill,Mirella Mourad,Rebecca Muhle,Gabriella Newes-Adeyi,Kimberly G Noble,Kally C O'Reilly,Anna A Penn,Lawrence Reichle,Ayesha Sania,Vera Semenova,Wendy G Silver,Grace Smotrich,Alan T Tita,Nim Tottenham,Michael Varner,Martha G Welch,Noelia Zork,Donna Garey,William P Fifer,Melissa S Stockwell,Catherine Monk,Fatimah Dawood,Dani Dumitriu

Abstract:Importance: Associations between prenatal SARS-CoV-2 exposure and neurodevelopmental outcomes have substantial public health relevance. A previous study found no association between prenatal SARS-CoV-2 infection and parent-reported infant neurodevelopmental outcomes, but standardized observational assessments are needed to confirm this finding. Objective: To assess whether mild or asymptomatic maternal SARS-CoV-2 infection vs no infection during pregnancy is associated with infant neurodevelopmental differences at ages 5 to 11 months. Design, setting, and participants: This cohort study included infants of mothers from a single-site prospective cross-sectional study (COVID-19 Mother Baby Outcomes [COMBO] Initiative) of mother-infant dyads and a multisite prospective cohort study (Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 in Pregnancy and Infancy [ESPI]) of pregnant individuals. A subset of ESPI participants was subsequently enrolled in the ESPI COMBO substudy. Participants in the ongoing COMBO study were enrolled beginning on May 26, 2020; participants in the ESPI study were enrolled from May 7 to November 3, 2021; and participants in the ESPI COMBO substudy were enrolled from August 2020 to March 2021. For the current analysis, infant neurodevelopment was assessed between March 2021 and June 2022. A total of 407 infants born to 403 mothers were enrolled (204 from Columbia University Irving Medical Center in New York, New York; 167 from the University of Utah in Salt Lake City; and 36 from the University of Alabama in Birmingham). Mothers of unexposed infants were approached for participation based on similar infant gestational age at birth, date of birth, sex, and mode of delivery to exposed infants. Exposures: Maternal symptomatic or asymptomatic SARS-CoV-2 infection. Main outcomes and measures: Infant neurodevelopment was assessed using the Developmental Assessment of Young Children, second edition (DAYC-2), adapted for telehealth assessment. The primary outcome was age-adjusted standard scores on 5 DAYC-2 subdomains: cognitive, gross motor, fine motor, expressive language, and receptive language. Results: Among 403 mothers, the mean (SD) maternal age at delivery was 32.1 (5.4) years; most mothers were of White race (240 [59.6%]) and non-Hispanic ethnicity (253 [62.8%]). Among 407 infants, 367 (90.2%) were born full term and 212 (52.1%) were male. Overall, 258 infants (63.4%) had no documented prenatal exposure to SARS-CoV-2 infection, 112 (27.5%) had confirmed prenatal exposure, and 37 (9.1%) had exposure before pregnancy or at an indeterminate time. In adjusted models, maternal SARS-CoV-2 infection during pregnancy was not associated with differences in cognitive (β = 0.31; 95% CI, -2.97 to 3.58), gross motor (β = 0.82; 95% CI, -1.34 to 2.99), fine motor (β = 0.36; 95% CI, -0.74 to 1.47), expressive language (β = -1.00; 95% CI, -4.02 to 2.02), or receptive language (β = 0.45; 95% CI, -2.15 to 3.04) DAYC-2 subdomain scores. Trimester of exposure and maternal symptom status were not associated with DAYC-2 subdomain scores. Conclusions and relevance: In this study, results of a novel telehealth-adapted observational neurodevelopmental assessment extended a previous finding of no association between prenatal exposure to maternal SARS-CoV-2 infection and infant neurodevelopment. Given the widespread and continued high prevalence of COVID-19, these data offer information that may be helpful for pregnant individuals who experience asymptomatic or mild SARS-CoV-2 infections.

Neurodevelopmental outcomes of infants after in utero exposure to SARS-CoV-2 or mRNA-COVID-19 vaccine compared with unexposed infants: a COVI-PREG prospective cohort study

Exposure to Maternal COVID-19 and Offspring Neurodevelopment Through Age 24 Months

Early life exposure to SARS-CoV-2 and offspring neurodevelopment: detecting a non-linear relationship requires a complex approach

Assessment of Neurodevelopment in Infants With and Without Exposure to Asymptomatic or Mild Maternal SARS-CoV-2 Infection During Pregnancy

Intrauterine exposure to SARS-CoV-2 infection and early newborn brain development

Neurodevelopmental delay in children exposed to maternal SARS-CoV-2 in-utero

In Utero Exposure to Maternal COVID-19 Vaccination and Offspring Neurodevelopment at 12 and 18 Months

Long-Term Growth and Neurodevelopmental Outcomes of Neonates Infected with SARS-CoV-2 during the COVID-19 Pandemic at 18–24 Months Corrected Age: A Prospective Observational Study

Newborn and Early Infant Outcomes Following Maternal COVID-19 Vaccination During Pregnancy

Prenatal maternal inactivated COVID-19 vaccination: the maternal and neonatal outcomes, a retrospective cohort study

ASSOCIATION BETWEEN BIRTH DURING THE COVID- 19 PANDEMIC AND NEURODEVELOPMENTAL STATUS OF INFANTS BETWEEN THE AGE OF 5-7 MONTHS WITH AND WITHOUT IN UTERO EXPOSURE TO MATERNAL SARS-COV-2 INFECTION

Assessment of newborn neuropsychomotor development born with exposure to SARS-CoV-2 in the perinatal period using the Bayley III scale at 6 months of age

Neonatal and maternal outcomes following SARS-CoV-2 infection and COVID-19 vaccination: a population-based matched cohort study

Risk of Hearing Loss in Neonates and Toddlers with in Utero Exposure to SARS-CoV-2

How Much Does SARS-CoV-2 Infection during Pregnancy Affect the Neonatal Brain, Heart, and Kidney? A Parallel between COVID-19, Vaccination, and Normal Pregnancy

Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022

Neonatal outcomes and indirect consequences following maternal SARS-CoV-2 infection in pregnancy: a systematic review

Perinatal Outcomes at Birth in Women Infected and Non-Infected with SARS-CoV-2: A Retrospective Study

Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes

Effect of COVID-19 vaccination and booster on maternal-fetal outcomes: a retrospective cohort study

Short-term Developmental Outcomes in Neonates Born to Mothers with COVID-19 from Wuhan, China